Porustobart is under clinical development by Harbour BioMed (Guangzhou) and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs for Melanoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Porustobart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Porustobart overview
HBM-4003 is under development for the treatment of advanced solid tumors including metastatic or unresectable metastatic melanoma, hepatocellular carcinoma and renal cell carcinoma, urothelial carcinoma, neuroendocrine cancer, neuroendocrine carcinoma and non-small cell lung cancer. The drug candidate is developed based on heavy chain only antibodies (HCAbs) transgenic mouse platform. It is administered by intravenous drip route and acts by targeting CTLA4.
Harbour BioMed (Guangzhou) overview
Harbour BioMed., a clinical-stage biopharmaceutical company that engaged in the provision of technology enabled healthcare services. The company is headquartered in China.
For a complete picture of Porustobart’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
